Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A known ✓ | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 1.00 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 1.00 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.53 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.47 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL613 | 1.00 | — | — | |
| Fumaric Acid SCHEMBL650322 | 1.00 | TSHR (1.00) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL2046430 | 1.00 | TSHR (1.00) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL8364460 | 1.00 | TSHR (1.00) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL2046432 | 1.00 | TSHR (1.00) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL20487516 | 1.00 | TSHR (1.00) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL1331192 | 1.00 | — | — | |
| Fumaric Acid SCHEMBL8364461 | 1.00 | TSHR (1.00) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL623596 | 1.00 | TSHR (1.00) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL2046433 | 1.00 | TSHR (1.00) | TSHRTP53EGLN1EGLN3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1177166-B1 | PROCESS FOR PREPARING (1R,2S,4R) -(-)-2- (2'- N,N-DIMETHYLAMINO -ETHOXY) -2- PHENYL -1,7,7-TRI- METHYL -BICYCLO 2.2.1 HEPTANE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF | EGIS GYOGYSZERGYAR NYILVANOSAN (HU) | 2008-02-20 | — | — | EP | disclosed |
| EP-1177167-B1 | HIGH PURITY (1R, 2S, 4R)-(-)-2-[(2'-(N,N-DIMETHYLAMINO)-ETHOXY)]-2-[PHENYL]-1,7,7-TRI-[METHYL]-BICYCLO[2.2.1]HEPTANE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF, PROCESS FOR THE PREPARATION OF THESE COMPOUNDS AND MEDICAMENTS CONTAINING THEM. | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2003-10-22 | — | — | EP | disclosed |
| US-6624201-B2 | For use in anxiolytic agents | ORION CORPORATION (FI) | 2003-09-23 | — | — | US | disclosed |
| EP-1052243-B1 | Process for preparing (1R, 2S, 4R)-(-)-2-[(2'-(N,N-dimethylamino)-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2003-07-30 | — | — | EP | disclosed |
| EP-1052245-B1 | High purity (1R, 2S, 4R)-(-)-2-[(2'-(N,N-dimethylamino)-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof, process for the preparation of these compounds and medicaments containing them | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2003-04-16 | — | — | EP | disclosed |
| US-20020040164-A1 | High purity (1R, 2S, 4R) -(-) -2- [ (2' -{N,N-dimethylamino} -ethoxy) ] -2- [phenyl] -1, 7,7 -tri - [methyl] -bicyclo [2.2.1] heptane and pharmaceutically acceptable acid addition salts thereof and a process for the preparation of these compounds as well as medicaments containing 1 or more of these compounds and their use | EGIS GYOGYSZERGYAR RT (HU) | 2002-04-04 | — | — | US | disclosed |
| EP-1177166-A2 | PROCESS FOR PREPARING (1R,2S,4R) -(-)-2- (2'- N,N-DIMETHYLAMINO -ETHOXY)] -2- PHENYL] -1,7,7-TRI- METHYL] -BICYCLO 2.2.1] HEPTANE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF | EGIS GYOGYSZERGYAR (HU) | 2002-02-06 | — | — | EP | disclosed |
| EP-1177167-A2 | HIGH PURITY (1R, 2S, 4R)-(-)-2-[(2'-(N,N-DIMETHYLAMINO)-ETHOXY)]-2-[PHENYL]-1,7,7-TRI-[METHYL]-BICYCLO[2.2.1]HEPTANE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF, PROCESS FOR THE PREPARATION OF THESE COMPOUNDS AND MEDICAMENTS CONTAINING THEM. | EGIS GYOGYSZERGYAR RT. (HU) | 2002-02-06 | — | — | EP | disclosed |
| US-6335469-B1 | COMPOUND CONTAINING NOT MORE THAN 0.2% OF (1R,3S,4R)-3-((2'-(N,N-DIMETHYLAMINO)-ETHYL))-1,7,7-TRIMETHYL -BICYCLO(2.2.1)HEPTANE-2-ONE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | ORION CORPORATION (FI) | 2002-01-01 | — | — | US | disclosed |
| US-6242386-B1 | DRUGS FORMED BY HYDROLYSIS OF CAMPHOR IN THE PRESENCE OF METALLORGANIC COMPOUNDS AND BASIC SALTS | EGIS Gyógyszergyár Rt. (HU) | 2001-06-05 | — | — | US | disclosed |
| WO-2000068183-A2 | HIGH PURITY (1R,2S,4R)-(-)-2-[(2'-{N,N-DIMETHYLAMINO}-ETHOXY)]-2-[PHENYL]-1,7,7-TRI-[METHYL]-BICYCLO[2.2.1]HEPTANE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF, PROCESS FOR THE PREPARATION OF THESE COMPOUNDS AND MEDICAMENTS CONTAINING THEM | EGIS Gyógyszergyár Rt. (HU) | 2000-11-16 | — | — | WO | disclosed |
| WO-2000068181-A2 | PROCESS FOR PREPARING (1R,2S,4R) -(-)-2-[(2'- {N,N-DIMETHYLAMINO} -ETHOXY)] -2-[PHENYL] -1,7,7-TRI- [METHYL] -BICYCLO [2.2.1] HEPTANE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF | EGIS Gyógyszergyár Rt. (HU) | 2000-11-16 | — | — | WO | disclosed |
| EP-1052243-A2 | Process for preparing (1R, 2S, 4R)-(-)-2-[(2'-(N,N-dimethylamino)-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof | EGIS GYOGYSZERGYAR RT. (HU) | 2000-11-15 | — | — | EP | disclosed |
| EP-1052245-A2 | High purity (1R, 2S, 4R)-(-)-2-[(2'-(N,N-dimethylamino)-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof, process for the preparation of these compounds and medicaments containing them | EGIS GYOGYSZERGYAR RT. (HU) | 2000-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040164-A1 | High purity (1R, 2S, 4R) -(-) -2- [ (2' -{N,N-dimethylamino} -ethoxy) ] -2- [phenyl] -1, 7,7 -tri - [methyl] -bicyclo [2.2.1] heptane and pharmaceutically acceptable acid addition salts thereof and a process for the preparation of these compounds as well as medicaments containing 1 or more of these compounds and their use | SLC7A1, ABCB11, PKD1 | KMT2A 1713/4885MEN1 341/4885TSHR 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.